Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - pleriksafors - multiple myeloma; hematopoietic stem cell transplantation - imunitātes stimulatori, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimethyl fumarate - multiple sclerosis, relapsing-remitting; multiple sclerosis - imūnsupresanti - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatas audzēji - citi hormonu antagonisti un tiem līdzīgas vielas - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - mikafungīns - pulveris infūziju šķīduma koncentrāta pagatavošanai - 100 mg

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - irinotekāna hidrohlorīda trihidrāts - koncentrāts infūziju šķīduma pagatavošanai - 20 mg/ml

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - fulvestrants - Šķīdums injekcijām pilnšļircē - 250 mg

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 12,5 μg

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 25 μg

Latvija - latviešu - Zāļu valsts aģentūra

accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 50 μg